Nykode Therapeutics (NYKD) 25th BioPharma Drug Discovery presentation summary

Diversified immunotherapy pipeline

• Advancing a randomized Phase 2 trial for head and neck cancer with Abili-T, targeting HPV-driven cancers.

• VB10.NEO individualized neoantigen therapy applicable across multiple cancer types.

• Preclinical antigen-specific immune tolerance program aims to transform autoimmune disease treatment.

• First interim readout for the immune tolerance program expected in 2027.

Proprietary modular platform and mechanism of action

• Platform features modular design with targeting, dimerization, antigenic, and modulatory units for tailored immune responses.

• APC-targeted therapies induce specific T cell responses, activating CD8 killer T cells for oncology or regulatory T cells for tolerance.

• Mechanism enables both immune activation (oncology) and immune suppression (tolerance) via APC targeting.

AI and machine learning integration

• In-house AI/ML models guide immunotherapy design, from target selection to peptide optimization.

• NeoSELECT platform uses ML and statistical methods to select optimal neoantigens, clinically validated in treated patients.

• AI-driven construct design leverages protein language models, graph neural networks, and explainable AI for transparency.

• Proprietary dataset of hundreds of constructs enables continuous model improvement.